Form 4: Edgewise CFO Nofi Granted Equity Awards

Edgewise Therapeutics CFO Michael Nofi received 43,750 Restricted Stock Units and 262,500 stock options, aligning his long-term interests with the company's performance.

Summary

• Michael Nofi, Chief Financial Officer of Edgewise Therapeutics, Inc. (EWTX), was granted equity awards.
• The awards include 43,750 Restricted Stock Units (RSUs) with a grant price of $0.00.
• The RSUs will vest in four equal annual installments, commencing on November 10, 2026.
• Additionally, 262,500 stock options were granted with an exercise price of $18.28 per share.
• The stock options will vest 1/4th on November 10, 2026, with the remaining shares vesting at 1/48th per month thereafter.
• Both the RSUs and stock options have an expiration date of November 10, 2035.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine disclosure of executive compensation, which is generally positive for aligning management interests but not a direct indicator of operational performance.

Positives

• The equity grants align the Chief Financial Officer's financial interests directly with the long-term performance and shareholder value of Edgewise Therapeutics.
• The multi-year vesting schedules for both RSUs and stock options incentivize long-term commitment and retention of key management personnel.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders if the stock options are exercised and RSUs vest, although this is a standard practice for executive compensation.

Risks

• Vesting of both Restricted Stock Units and stock options is contingent upon the Reporting Person continuing as a service provider through each vest date, meaning the awards could be forfeited if employment ceases.

Future Outlook

The equity awards are structured to incentivize the Chief Financial Officer's continued service and focus on long-term value creation for Edgewise Therapeutics, with vesting schedules extending over several years.

Industry Context

The granting of Restricted Stock Units and stock options to a Chief Financial Officer is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and motivate top talent while aligning their interests with shareholders.

Comparison to Industry Standards

• The structure of these equity grants, including a mix of RSUs and stock options with multi-year vesting schedules, is consistent with standard executive compensation practices observed across publicly traded biotechnology companies.
• The vesting conditions tied to continued service are typical for such awards, ensuring that the incentives remain aligned with the executive's ongoing contribution to the company.

Stakeholder Impact

• Shareholders: The grants align the CFO's interests with shareholder value creation, potentially leading to more focused long-term decision-making. However, future exercise of options or vesting of RSUs could result in minor dilution.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs, potentially impacting morale and retention.

Next Steps

• The first tranche of Restricted Stock Units and stock options will vest on November 10, 2026.
• Subsequent vesting events for RSUs will occur annually, and for stock options, monthly, following the initial vesting date.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, Michael Nofi, Chief Financial Officer, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Executive Compensation, Form 4